User menu

Country, sex, EDSS change and therapy choice independently predict treatment discontinuation in multiple sclerosis and clinically isolated syndrome

Bibliographic reference Meyniel, Claire ; Spelman, Timothy ; Jokubaitis, Vilija G ; Trojano, Maria ; Izquierdo, Guillermo ; et. al. Country, sex, EDSS change and therapy choice independently predict treatment discontinuation in multiple sclerosis and clinically isolated syndrome. In: PLoS One, Vol. 7, no. 6, p. e38661 [1-8] (2012)
Permanent URL
  1. M Brodsky, Arch Neurol, 65, 727 (2008)
  2. Filippi Massimo, Rovaris Marco, Inglese Matilde, Barkhof Frederik, De Stefano Nicola, Smith Steve, Comi Giancarlo, Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial, 10.1016/s0140-6736(04)17271-1
  3. Jacobs Lawrence D., Beck Roy W., Simon Jack H., Kinkel R. Phillip, Brownscheidle Carol M., Murray Thomas J., Simonian Nancy A., Slasor Peter J., Sandrock Alfred W., Intramuscular Interferon Beta-1A Therapy Initiated during a First Demyelinating Event in Multiple Sclerosis, 10.1056/nejm200009283431301
  4. , IM interferon  -1a delays definite multiple sclerosis 5 years after a first demyelinating event, 10.1212/
  5. Comi Giancarlo, Filippi Massimo, Barkhof Frederik, Durelli Luca, Edan Gilles, Fernández Oscar, Hartung Hans-Peter, Seeldrayers Pierrette, Sørensen Per Soelberg, Rovaris Marco, Martinelli Vittorio, Hommes Otto R, Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study, 10.1016/s0140-6736(00)04725-5
  6. Kappos L., Polman C. H., Freedman M. S., Edan G., Hartung H. P., Miller D. H., Montalban X., Barkhof F., Bauer L., Jakobs P., Pohl C., Sandbrink R., , Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes, 10.1212/01.wnl.0000237641.33768.8d
  7. Comi G, Martinelli V, Rodegher M, Moiola L, Bajenaru O, Carra A, Elovaara I, Fazekas F, Hartung HP, Hillert J, King J, Komoly S, Lubetzki C, Montalban X, Myhr KM, Ravnborg M, Rieckmann P, Wynn D, Young C, Filippi M, Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial, 10.1016/s0140-6736(09)61259-9
  8. Reynolds Matthew W., Stephen Reejis, Seaman Chris, Rajagopalan Kitty, Persistence and adherence to disease modifying drugs among patients with multiple sclerosis, 10.1185/03007990903554257
  9. DC Mohr, 5, 192 (1999)
  10. Portaccio E., Zipoli V., Siracusa G., Sorbi S., Amato M.P., Long-Term Adherence to Interferon β Therapy in Relapsing-Remitting Multiple Sclerosis, 10.1159/000111875
  11. Ruggieri R. M., Settipani N., Viviano L., Attanasio M., Giglia L., Almasio P., La Bella V., Piccoli F., Long-term interferon-β treatment for multiple sclerosis, 10.1007/s10072-003-0190-3
  12. Kleinman Nathan L., Beren Ian A., Rajagopalan Krithika, Brook Richard A., Medication adherence with disease modifying treatments for multiple sclerosis among US employees, 10.3111/13696998.2010.527588
  13. Río Jordi, Porcel Joana, Téllez Nieves, Sánchez-Betancourt Angela, Tintoré M ar, Arévalo M Jesús, Nos Carlos, Montalban Xavier, Factors related with treatment adherence to interferon b and glatiramer acetate therapy in multiple sclerosis, 10.1191/1352458505ms1173oa
  14. Butzkueven H, Chapman J, Cristiano E, Grand’Maison F, Hoffmann M, Izquierdo G, Jolley D, Kappos L, Leist T, Pöhlau D, Rivera V, Trojano M, Verheul F, Malkowski J-P, MSBase: an international, online registry and platform for collaborative outcomes research in multiple sclerosis, 10.1177/1352458506070775
  15. Polman Chris H., Reingold Stephen C., Edan Gilles, Filippi Massimo, Hartung Hans-Peter, Kappos Ludwig, Lublin Fred D., Metz Luanne M., McFarland Henry F., O'Connor Paul W., Sandberg-Wollheim Magnhild, Thompson Alan J., Weinshenker Brian G., Wolinsky Jerry S., Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”, 10.1002/ana.20703
  16. JF Kurtzke, 33, 1444 (1983)
  17. Hurwitz B. J., Registry studies of long-term multiple sclerosis outcomes: Description of key registries, 10.1212/wnl.0b013e3182050225
  18. Confavreux C, Compston D A, Hommes O R, McDonald W I, Thompson A J, EDMUS, a European database for multiple sclerosis., 10.1136/jnnp.55.8.671
  19. Bronnum-Hansen H., Koch-Henriksen N., Hyllested K., Survival of patients with multiple sclerosis in Denmark: A nationwide, long-term epidemiologic survey, 10.1212/wnl.44.10.1901
  20. Tremlett H. L., Oger J., Interrupted therapy: Stopping and switching of the  -interferons prescribed for MS, 10.1212/01.wnl.0000078885.05053.7d
  21. Milanese C, A post-marketing study on interferon   1b and 1a treatment in relapsing-remitting multiple sclerosis: different response in drop-outs and treated patients, 10.1136/jnnp.74.12.1689
  22. K Costello, Medscape J Med, 10, 225 (2008)
  23. Ross A. P., Tolerability, adherence, and patient outcomes, 10.1212/wnl.0b013e31818f3dcb
  24. C Heesen, 10(6), 643 (2004)
  25. A Giordano, 86 (2008)
  26. Arbizu T., Alvarez-Cermeno J. C., Decap G., Fernandez O., Uria D. F., Garcia Merino A., Izquierdo G., Montalban X., Interferon beta-1b treatment in patients with relapsing-remitting multiple sclerosis under a standardized protocol in Spain, 10.1034/j.1600-0404.2000.102004209.x
  27. Miller David H, Brain atrophy, interferon beta, and treatment trials in multiple sclerosis, 10.1016/s0140-6736(04)17285-1